Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer

PR Newswire May 23, 2013

NW Bio Initiates Phase III DCVax®-L Brain Cancer Trial In Europe: King's College Hospital In The UK Is First Site To Open

PR Newswire May 16, 2013

Interviews Of NW Bio's CEO, On The Floor Of The New York Stock Exchange, Now Available Online

PR Newswire May 3, 2013

RedChip Emerging Growth Showcase Takes Place May 1

Globe Newswire April 23, 2013

NW Bio Announces That Another Brain Cancer Patient From Phase I/II DCVax®-L Trials Has Surpassed Ten-Year Cancer-Free Survival

PR Newswire April 18, 2013

NW Bio Announces $10 Million Registered Direct Offering

PR Newswire April 18, 2013

NW Bio's Phase III Trial With DCVax®-L For Brain Cancer "Adopted" As A National Priority Trial In UK

PR Newswire April 16, 2013

NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position

PR Newswire April 8, 2013

NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference

PR Newswire March 19, 2013

NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells

PR Newswire March 18, 2013

NW Bio Establishes Cross-Border Manufacturing And Distribution For DCVax® In Europe

PR Newswire March 12, 2013

NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials

PR Newswire March 7, 2013

NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe

PR Newswire February 15, 2013

NW Bio To Present At 15th Annual BIO CEO & Investor Conference

PR Newswire February 11, 2013

NW Bio Presenting At Phacilitate Cell Therapy Forum

PR Newswire January 29, 2013

Before the Crowd, How we Found CLF, SCCO, NWBO and GLW

Marketwired January 28, 2013

The Reason It Trades, What's Moving UAMY, NWBO, PAMT and MT

Marketwired January 14, 2013

The Real Story Behind ISIS, BIIB, NWBO and BMY

Marketwired January 11, 2013

Perfect Trade Setups, How to Play VVI, CLF, NWBO and SLB

Marketwired January 8, 2013

The Real Story Behind AVEO, CLSN, CYCC and NWBO

Marketwired December 26, 2012